Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.
Also called NCT06402851
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,500 participants
- Sponsor
- Registry
-
NCT06402851
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Recruiting
Technical summary
Registry record NCT06402851. Randomized; single masking; primary purpose treatment. Start 2024-12-18 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
- Acronym
- VISIONAIRE
- Condition
- Atrium; Fibrillation
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Anticoagulant Oral
- Lead sponsor
- Hospital Sirio-Libanes
- Collaborator
- Daiichi Sankyo
Record details
- Record id
cardio:ct-nct06402851- Content hash
826238a91671ddb87282934495726631c183d4719a03b3b67fe55af25bd1e28b